News Releases

Date	Title and Summary	View
May 24, 2022	Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
May 23, 2022	New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
May 18, 2022	New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
May 12, 2022	Johnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
May 11, 2022	Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company The Company has also appointed Paul Ruh as CFO Designate Mongon and Ruh to Assume New Leadership Roles Upon the Completion of the Planned Separation of the Consumer Health Business Planned Separation Expected to Occur in 2023 NEW BRUNSWICK, N.J. , May 11, 2022 /PRNewswire/ -- Johnson & Johnson (the
May 05, 2022	MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development
May 02, 2022	Johnson & Johnson to Participate in the Bernstein 38th Annual Strategic Decisions Conference
Apr 20, 2022	Johnson & Johnson to Participate in the UBS Global Healthcare Conference
Apr 19, 2022	Johnson & Johnson Reports Q1 2022 Results
Apr 19, 2022	Johnson & Johnson Announces Dividend Increase of 6.6%